ArticleCommunications medicine2025
Longitudinal study of risk factors predicting cannabis use disorder in UK young adults and adolescents.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Operationalizing ASSIST-based indicators to estimate the prevalence and correlates of problematic cannabis involvement among U.S. college students.Journal of cannabis research · 2026Article
- Redefining Recovery: The Expanding Cannabis Landscape and Its Implications for the California Sober Approach in Addiction.International journal of mental health and addiction · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCannabis use disorder (CUD) affects up to 1 in 5 people who try cannabis. In order to develop effective interventions to prevent and treat CUD, it is important to identify the factors that predict it. This longitudinal study investigated whether eight potential risk factors predicted CUD levels at 12-month follow-up.
methodsParticipants were 232 young adults (26-29 years) and adolescents (16-17 years) (48%/52% males/females) who took part in both the baseline and 12-month follow-up sessions of the London-based 'CannTeen' study. Half of the participants (n = 117) used cannabis 1-7 days/week at baseline and the other half had used cannabis maximum 10 times in their life. CUD was measured with the Mini Neuropsychiatric interview for DSM-5 CUD, which was used to categorise participants into no, mild, moderate, or severe CUD levels. Ordinal logistic regression was used to explore whether baseline CUD (yes/no), age-group, gender, days/week of cannabis use, problematic alcohol use, problematic tobacco use, past-year negative life events, and the COVID-19 lockdown predicted 12-month CUD levels in the full sample and in only those who used cannabis minimum once per week at baseline.
resultsHere we show that adolescent age (odds ratio = 3.26, p < 0.001) and CUD at baseline (odds ratio = 45.15, p < 0.001) predict higher CUD levels at follow-up. We do not find evidence to support associations with other factors. The same pattern of results is found when including only participants who used cannabis at baseline.
conclusionsCUD prevention and treatment should be targeted towards adolescents, who have a significantly greater risk of CUD than young adults.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.